The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation beats earnings expectations. Reported EPS is ...

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

Boston Scientific increased its annual profit forecast on Wednesday, fueled by strong demand for its cardiac implants, but temporarily halted a pivotal heart equipment study citing unexpected events.